{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:09:03Z","timestamp":1788754143936,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In the United States, meningococcal serogroup B (MenB) vaccination is recommended for 16\u201323-year-olds based on shared clinical decision-making. We estimated series completion among individuals initiating MenB vaccination for the 2 available vaccines: MenB 4-component (MenB-4C, doses at 0 and \u22651 month) and MenB factor H binding protein (MenB-FHbp, doses at 0 and 6 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective health insurance claims data analysis included 16\u201323-year-olds who initiated MenB vaccination (index date) during January 2017 to November 2018 (MarketScan Commercial Claims and Encounters Database) or January 2017 to September 2018 (MarketScan Multi-State Medicaid Database) and had continuous enrollment for \u22656 months before and \u226515 months after index. The main outcome was MenB vaccine series completion within 15 months. Among noncompleters, preventive care\/well-child and vaccine administrative office visits were identified as potential missed opportunities for series completion. Robust Poisson regression models identified independent predictors of series completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the Commercial (n = 156,080) and Medicaid (n = 57,082) populations, series completion was 56.7% and 44.7%, respectively, and was higher among those who initiated MenB-4C versus MenB-FHbp (61.1% versus 49.8% and 47.8% versus 33.9%, respectively; both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Among noncompleters, 40.2% and 34.7% of the Commercial and Medicaid populations, respectively, had \u22651 missed opportunity for series completion. Receipt of MenB-4C and younger age were independently associated with a higher probability of series completion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Series completion rates were suboptimal but were higher among those who initiated MenB-4C. To maximize the benefits of MenB vaccination, interventions to improve completion and reduce missed opportunities should be implemented.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000003455","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T19:08:02Z","timestamp":1643310482000},"page":"e158-e165","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States"],"prefix":"10.1097","volume":"41","author":[{"given":"Elizabeth R.","family":"Packnett","sequence":"first","affiliation":[{"name":"IBM Watson Health, Life Sciences, Outcomes Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Life Sciences, Outcomes Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilwan","family":"Kim","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Life Sciences, Custom Data Analytics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Novy","sequence":"additional","affiliation":[{"name":"GSK, US Medical Affairs, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Morgan","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Life Sciences, Outcomes Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnenna","family":"Chime","sequence":"additional","affiliation":[{"name":"GSK, US Medical Affairs, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinaz","family":"Ghaswalla","sequence":"additional","affiliation":[{"name":"GSK, US Health Outcomes & Epidemiology \u2013 Vaccines, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61779-346-2_2","article-title":"Classification and pathogenesis of meningococcal infections.","volume":"799","author":"Brandtzaeg","year":"2012","journal-title":"Methods Mol Biol"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis.","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers.","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1904.111799","article-title":"Description and nomenclature of Neisseria meningitidis capsule locus.","volume":"19","author":"Harrison","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease-United States, 1996-2015.","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"RR-7","key":"R7-20250615","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R8-20250615","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines \u2013 Advisory Committee on Immunization Practices (ACIP), 2010.","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020.","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.15585\/mmwr.mm6933a1","article-title":"National, Regional, State, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2019.","volume":"69","author":"Elam-Evans","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp Serogroup B meningococcal vaccine - advisory committee on immunization practices, 2016.","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.vaccine.2019.06.065","article-title":"Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: a retrospective analysis by vaccine and payer type.","volume":"37","author":"Packnett","year":"2019","journal-title":"Vaccine"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/QAI.0b013e3181adcb01","article-title":"Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy.","volume":"51","author":"Domingo","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.vaccine.2021.03.071","article-title":"Meningococcal B vaccination coverage among older adolescents in the United States.","volume":"39","author":"La","year":"2021","journal-title":"Vaccine"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MLR.0000000000000855","article-title":"Insurance type and access to health care providers and appointments under the affordable care act.","volume":"56","author":"Alcal\u00e1","year":"2018","journal-title":"Med Care"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2105\/AJPH.2016.303156","article-title":"Access and quality of care by insurance type for low-income adults before the affordable care act.","volume":"106","author":"Nguyen","year":"2016","journal-title":"Am J Public Health"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3122\/jabfm.2020.04.190464","article-title":"Human papillomavirus (HPV) vaccination initiation and completion among adult males in the United States.","volume":"33","author":"Guo","year":"2020","journal-title":"J Am Board Fam Med"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.vaccine.2019.12.030","article-title":"Factors influencing human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid.","volume":"38","author":"Inguva","year":"2020","journal-title":"Vaccine"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ajic.2019.03.014","article-title":"Characteristics associated with human papillomavirus vaccination initiation and completion among young adults.","volume":"47","author":"Ding","year":"2019","journal-title":"Am J Infect Control"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1080\/21645515.2018.1533778","article-title":"Achieving high HPV vaccine completion rates in a pediatric clinic population.","volume":"15","author":"Berenson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pvr.2015.10.001","article-title":"HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.","volume":"2","author":"Liu","year":"2016","journal-title":"Papillomavirus Res"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/0033354919867734","article-title":"Completion of the human papillomavirus vaccination series among adolescent users and nonusers of school-based health centers.","volume":"134","author":"Munn","year":"2019","journal-title":"Public Health Rep"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1080\/21645515.2018.1467203","article-title":"Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States.","volume":"14","author":"Adjei Boakye","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/13557858.2018.1427703","article-title":"Racial\/ethnic disparities in human papillomavirus vaccination initiation and completion among U.S. women in the post-Affordable Care Act era.","volume":"25","author":"Ag\u00e9nor","year":"2020","journal-title":"Ethn Health"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.acap.2019.05.002","article-title":"Disparities in human papillomavirus vaccine series completion by adolescent males: a retrospective cohort study.","volume":"20","author":"Agawu","year":"2020","journal-title":"Acad Pediatr"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amepre.2020.09.005","article-title":"Geographic variation in human papillomavirus vaccination initiation and completion among young adults in the U.S.","volume":"60","author":"Adjei Boakye","year":"2021","journal-title":"Am J Prev Med"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1353\/hpu.2019.0090","article-title":"Text and email messaging for increasing human papillomavirus vaccine completion among uninsured or medicaid-insured adolescents in rural Eastern North Carolina.","volume":"30","author":"Richman","year":"2019","journal-title":"J Health Care Poor Underserved"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/003335491613100304","article-title":"Understanding non-completion of the human papillomavirus vaccine series: parent-reported reasons for why adolescents might not receive additional doses, United States, 2012.","volume":"131","author":"Clark","year":"2016","journal-title":"Public Health Rep"},{"key":"R33-20250615","doi-asserted-by":"crossref","first-page":"389","DOI":"10.15585\/mmwr.mm7011e2","article-title":"COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons - United States, December 14, 2020-February 14, 2021.","volume":"70","author":"Kriss","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R34-20250615","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jiph.2012.11.001","article-title":"Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort.","volume":"6","author":"Rock","year":"2013","journal-title":"J Infect Public Health"},{"key":"R35-20250615","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jadohealth.2016.09.011","article-title":"Effects of phone and text message reminders on completion of the human papillomavirus vaccine series.","volume":"60","author":"Rand","year":"2017","journal-title":"J Adolesc Health"},{"key":"R36-20250615","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jogn.2018.06.001","article-title":"Development of the nowiknow mobile application to promote completion of HPV vaccine series among young adult women.","volume":"47","author":"Teitelman","year":"2018","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"R37-20250615","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/21645515.2019.1632679","article-title":"Determinants of meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations.","volume":"16","author":"Cheng","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"R38-20250615","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3122\/jabfm.2015.03.140082","article-title":"Impact of an electronic health record (ehr) reminder on human papillomavirus (HPV) Vaccine initiation and timely completion.","volume":"28","author":"Ruffin","year":"2015","journal-title":"J Am Board Fam Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T12:04:22Z","timestamp":1749989062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003455","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}